Design and Development of a New Type of Hybrid PLGA/Lipid Nanoparticle as an Ursolic Acid Delivery System against Pancreatic Ductal Adenocarcinoma Cells.
PLGA
cancer
nanoparticles
nanotechnology
pancreatic cancer
terpenoids
ursolic acid
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
16 May 2022
16 May 2022
Historique:
received:
21
03
2022
revised:
08
05
2022
accepted:
13
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
1
6
2022
Statut:
epublish
Résumé
Despite many attempts, trials, and treatment procedures, pancreatic ductal adenocarcinoma (PDAC) still ranks among the most deadly and treatment-resistant types of cancer. Hence, there is still an urgent need to develop new molecules, drugs, and therapeutic methods against PDAC. Naturally derived compounds, such as pentacyclic terpenoids, have gained attention because of their high cytotoxic activity toward pancreatic cancer cells. Ursolic acid (UA), as an example, possesses a wide anticancer activity spectrum and can potentially be a good candidate for anti-PDAC therapy. However, due to its minimal water solubility, it is necessary to prepare an optimal nano-sized vehicle to overcome the low bioavailability issue. Poly(lactic-co-glycolic acid) (PLGA) polymeric nanocarriers seem to be an essential tool for ursolic acid delivery and can overcome the lack of biological activity observed after being incorporated within liposomes. PLGA modification, with the addition of PEGylated phospholipids forming the lipid shell around the polymeric core, can provide additional beneficial properties to the designed nanocarrier. We prepared UA-loaded hybrid PLGA/lipid nanoparticles using a nanoprecipitation method and subsequently performed an MTT cytotoxicity assay for AsPC-1 and BxPC-3 cells and determined the hemolytic effect on human erythrocytes with transmission electron microscopic (TEM) visualization of the nanoparticles and their cellular uptake. Hybrid UA-loaded lipid nanoparticles were also examined in terms of their stability, coating dynamics, and ursolic acid loading. We established innovative and repeatable preparation procedures for novel hybrid nanoparticles and obtained biologically active nanocarriers for ursolic acid with an IC50 below 20 µM, with an appropriate size for intravenous dosage (around 150 nm), high homogeneity of the sample (below 0.2), satisfactory encapsulation efficiency (up to 70%) and excellent stability. The new type of hybrid UA-PLGA nanoparticles represents a further step in the development of potentially effective PDAC therapies based on novel, biologically active, and promising triterpenoids.
Identifiants
pubmed: 35628352
pii: ijms23105536
doi: 10.3390/ijms23105536
pmc: PMC9143619
pii:
doi:
Substances chimiques
Lipid Nanoparticles
0
Liposomes
0
Triterpenes
0
Polylactic Acid-Polyglycolic Acid Copolymer
1SIA8062RS
Polyglycolic Acid
26009-03-0
Lactic Acid
33X04XA5AT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Front Mol Biosci. 2020 Mar 06;7:33
pubmed: 32211418
Drugs. 2020 May;80(7):647-669
pubmed: 32306207
Int J Mol Sci. 2014 Feb 28;15(3):3640-59
pubmed: 24590126
Mol Cancer Res. 2007 Sep;5(9):943-55
pubmed: 17855663
PLoS One. 2012;7(12):e53178
pubmed: 23300887
Mol Pharm. 2009 Jan-Feb;6(1):190-201
pubmed: 19035785
Biol Pharm Bull. 2012;35(9):1432-9
pubmed: 22975492
Cancer Res. 2003 Aug 1;63(15):4375-83
pubmed: 12907607
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015 Sep-Oct;7(5):655-77
pubmed: 25707913
Korean J Physiol Pharmacol. 2018 May;22(3):235-248
pubmed: 29719446
Cancer Invest. 2009 Aug;27(7):723-33
pubmed: 19440893
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):427-43
pubmed: 23872180
Arch Med Sci. 2018 Jun;14(4):910-919
pubmed: 30002710
Front Oncol. 2021 Jul 15;11:688377
pubmed: 34336673
Cell Signal. 2009 Nov;21(11):1541-7
pubmed: 19298854
Int J Nanomedicine. 2014 Feb 20;9:1025-37
pubmed: 24591825
World J Hepatol. 2011 Sep 27;3(9):228-49
pubmed: 21969877
Plant Cell Rep. 2017 Dec;36(12):1917-1928
pubmed: 28913707
Molecules. 2019 May 26;24(10):
pubmed: 31130671
J Drug Deliv. 2011;2011:326497
pubmed: 21490748
Adv Drug Deliv Rev. 2011 Mar 18;63(3):136-51
pubmed: 20441782
J Nutr. 1999 Mar;129(3):775S-778S
pubmed: 10082788
Molecules. 2020 Oct 14;25(20):
pubmed: 33066675
Pharmaceutics. 2018 May 18;10(2):
pubmed: 29783687
Radiat Oncol. 2019 Aug 8;14(1):141
pubmed: 31395068
Science. 2009 Jun 12;324(5933):1457-61
pubmed: 19460966
Biol Pharm Bull. 2018;41(6):899-907
pubmed: 29863078
Int J Pharm. 2001 Jun 19;221(1-2):143-52
pubmed: 11397575
J Oncol. 2019 Dec 06;2019:5832309
pubmed: 31885579
J Drug Target. 2002 Nov;10(7):539-48
pubmed: 12683721
Cancer Res. 2000 May 1;60(9):2399-404
pubmed: 10811116
Crit Rev Ther Drug Carrier Syst. 2013;30(3):257-76
pubmed: 23614648
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Biomacromolecules. 2007 Nov;8(11):3651-60
pubmed: 17958441
Nat Med. 2016 May;22(5):497-505
pubmed: 27089513
Biomaterials. 2009 May;30(14):2790-8
pubmed: 19232712
Oncotarget. 2016 Mar 15;7(11):13182-96
pubmed: 26909608
Materials (Basel). 2021 Aug 29;14(17):
pubmed: 34501007
Cancers (Basel). 2017 Nov 16;9(11):
pubmed: 29144412
Polymers (Basel). 2011 Sep 1;3(3):1377-1397
pubmed: 22577513
Int J Oncol. 2003 Jul;23(1):105-12
pubmed: 12792782
Int J Nanomedicine. 2006;1(3):297-315
pubmed: 17717971
Biomater Res. 2016 Oct 31;20:34
pubmed: 27807476
Materials (Basel). 2020 Dec 19;13(24):
pubmed: 33352809
Front Pharmacol. 2018 Nov 02;9:1260
pubmed: 30450050
J Nanobiotechnology. 2022 Jan 21;20(1):45
pubmed: 35062958
Res Pharm Sci. 2019 Oct 04;14(5):459-470
pubmed: 31798663
Sci Rep. 2020 Oct 2;10(1):16425
pubmed: 33009477
Eur J Pharm Sci. 2021 Aug 1;163:105838
pubmed: 33845119
Eur J Med Chem. 2019 Aug 15;176:268-291
pubmed: 31103904
Oncotarget. 2020 Mar 10;11(10):924-941
pubmed: 32206189
Curr Drug Targets. 2010 Jun;11(6):733-44
pubmed: 20298150
Cancers (Basel). 2018 Sep 06;10(9):
pubmed: 30200666
Mol Med Rep. 2013 May;7(5):1673-7
pubmed: 23483134
Int J Mol Sci. 2017 Jun 22;18(7):
pubmed: 28640192
Soft Matter. 2008;4(9):1787-1791
pubmed: 19756178
Biomaterials. 2000 Dec;21(23):2475-90
pubmed: 11055295
Hum Exp Toxicol. 2019 Jul;38(7):785-793
pubmed: 30977399
Sci Rep. 2019 Feb 4;9(1):1310
pubmed: 30718678
Cancer Res. 2011 Jul 15;71(14):5020-9
pubmed: 21586612
Nanomedicine (Lond). 2008 Oct;3(5):703-17
pubmed: 18817471
Nanoscale Res Lett. 2013 Feb 22;8(1):102
pubmed: 23432972
Oncotarget. 2014 Nov 30;5(22):10969-75
pubmed: 25473891
Mol Pharm. 2019 Jul 1;16(7):2858-2871
pubmed: 31136710
Theranostics. 2019 Oct 17;9(26):8018-8025
pubmed: 31754378
Sci Technol Adv Mater. 2019 Jun 26;20(1):710-724
pubmed: 31275462
N Engl J Med. 2018 Dec 20;379(25):2395-2406
pubmed: 30575490
SAGE Open Med. 2014 Sep 02;2:2050312114546924
pubmed: 26770737
J Nutr Biochem. 2013 Apr;24(4):706-12
pubmed: 22841540
Front Cell Dev Biol. 2021 Oct 27;9:748631
pubmed: 34778259
World J Gastrointest Oncol. 2011 Nov 15;3(11):153-64
pubmed: 22110842
Gut. 2013 Jan;62(1):112-20
pubmed: 22466618
Materials (Basel). 2019 Jun 18;12(12):
pubmed: 31216635
Front Oncol. 2019 Nov 08;9:1153
pubmed: 31781485
J Agric Food Chem. 2016 Jun 1;64(21):4220-6
pubmed: 27171502
Br J Clin Pharmacol. 2013 Mar;75(3):588-602
pubmed: 22897361
Nanomedicine (Lond). 2015 Feb;10(3):447-63
pubmed: 25707978
Front Pharmacol. 2016 Jun 28;7:185
pubmed: 27445821
ACS Nano. 2008 Aug;2(8):1696-702
pubmed: 19206374
J Thorac Cardiovasc Surg. 2000 Apr;119(4 Pt 1):795-803
pubmed: 10733772